AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15933410 — intervention group
Group type: EXPERIMENTAL
Intervention: Education campaign by a local tractor and equipment dealership promoting ROPS and seatbelt retrofit kits for older tractors.
Number of subjects: 0
Study 12858776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sini decoction
Number of subjects: 63
Study 12858776 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 63
Study 10500942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (group COPA, n = 30)
Number of subjects: 60
Study 10500942 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask (group LMA, n = 30)
Number of subjects: 60
Study 8780536 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 status in patients with recurrent disease
Number of subjects: 36
Study 8780536 — intervention group
Group type: COMPARATOR
Intervention: p53 status in control group (without recurrent disease)
Number of subjects: 36
Study 8780536 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of detection techniques
Number of subjects: 36
Study 8780536 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall p53 alteration
Number of subjects: 36
Study 1600965 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone bolus dose (50 micrograms kg‐1) followed by infusion at rates of 0.375, 0.5 or 0.75 microgram kg‐1 min‐1
Number of subjects: 99
Study 1600965 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone infusion
Number of subjects: 99
Study 6389233 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin infusion (CONT: 0.4 mU X kg‐1 X min‐1)
Number of subjects: 7
Study 6389233 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion (PULS: 0.8 mU X kg‐1 X min‐1, 7.5 min of 15)
Number of subjects: 7
Study 31918639 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth mindset of personality intervention
Number of subjects: 60
Study 31330804 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 13
Study 31330804 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee plus isolated CAF (DECAF + CAF)
Number of subjects: 13
Study 31330804 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee plus isolated CAF plus soy oil (DECAF + CAF + SO)
Number of subjects: 13
Study 31330804 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee plus isolated CAF plus extra virgin coconut oil (DECAF + CAF + CO)
Number of subjects: 13
Study 30126458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine plus celecoxib
Number of subjects: 200
Study 30126458 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine plus placebo
Number of subjects: 200
Study 27084832 — intervention group
Group type: EXPERIMENTAL
Intervention: One (low intensity) IMT session for five months
Number of subjects: 15
Study 27084832 — intervention group
Group type: EXPERIMENTAL
Intervention: Three weekly IMT sessions (high intensity) for five months
Number of subjects: 15
Study 27084832 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 15
Study 25135542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1% plus dexamethasone 0.1%
Number of subjects: 152
Study 25135542 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1% alone
Number of subjects: 152
Study 22295934 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 16
Study 22295934 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 16
Study 19326064 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus approach for total knee replacement
Number of subjects: 100
Study 19326064 — intervention group
Group type: COMPARATOR
Intervention: Parapatellar approach for total knee replacement
Number of subjects: 100
Study 17366918 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative amino acid infusion
Number of subjects: 0
Study 17366918 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative amino acid infusion
Number of subjects: 0
Study 17366918 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 0
Study 17366918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose infusion
Number of subjects: 0
Study 16422256 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming and fluid warming system
Number of subjects: 40
Study 16422256 — intervention group
Group type: COMPARATOR
Intervention: Conventional cotton blanket
Number of subjects: 40
Study 12002412 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (12 h infusion: bolus 0.75 microg/kg followed by 0.75 microg/kg/h)
Number of subjects: 25
Study 12002412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9735391 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT group) with low-dose oral UFT and continuous venous 5FU infusion.
Number of subjects: 42
Study 9735391 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (NCT group), n=28.
Number of subjects: 42
Study 8903669 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and indapamide or matching placebos
Number of subjects: 6000
Study 8903669 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril alone or matching placebo
Number of subjects: 6000
Study 2109573 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (single 400‐mg dose)
Number of subjects: 89
Study 2109573 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ceftriaxone (250‐mg dose)
Number of subjects: 89
Study 6787417 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10 mg twice daily)
Number of subjects: 1884
Study 6787417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study 31900274 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (once per day for 6 months)
Number of subjects: 0
Study 31900274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once per day for 6 months)
Number of subjects: 0
Study 31287556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate with 200 mL mannitol
Number of subjects: 40
Study 31287556 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 40
Study 27621150 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05190457 100 mg
Number of subjects: 70
Study 27621150 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05190457 150 mg
Number of subjects: 70
Study 27621150 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05190457 ≥50 mg
Number of subjects: 70
Study 27621150 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05190457
Number of subjects: 70
Study 27621150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25605582 — intervention group
Group type: EXPERIMENTAL
Intervention: APBI using IMRT
Number of subjects: 520
Study 25605582 — intervention group
Group type: COMPARATOR
Intervention: WBI
Number of subjects: 520
Study 24481579 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg iv dexketoprofen trometamol
Number of subjects: 114
Study 24481579 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg iv paracetamol
Number of subjects: 114
Study 24481579 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 114
Study 22162339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) group program for RA fatigue
Number of subjects: 38
Study 19074913 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 1-4 mg/day
Number of subjects: 31
Study 19074913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16612837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivariate growth curve method for estimating trajectories
Number of subjects: 0
Study 15893008 — intervention group
Group type: EXPERIMENTAL
Intervention: PORT (5040 cGy in 28 daily fractions)
Number of subjects: 488
Study 15893008 — intervention group
Group type: EXPERIMENTAL
Intervention: CPORT (PORT plus four cycles of cisplatin (60 mg/m2, day 1) and etoposide (120 mg/m2, days 1‐3) administered concurrently)
Number of subjects: 488
Study 15893008 — intervention group
Group type: COMPARATOR
Intervention: Age and gender matched controls
Number of subjects: 488
Study 15893008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (PORT and CPORT)
Number of subjects: 488
Study 12139537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine 30 ml with 30 mg ketamine (Group K)
Number of subjects: 60
Study 12139537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine 30 ml (Group P)
Number of subjects: 60
Study 12139537 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine with 30 mg ketamine i.v. (Group C)
Number of subjects: 60
Study 9801236 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid
Number of subjects: 0
Study 9801236 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 7630678 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) at doses ranging from 0.125 to 4 mg/kg/day in two divided doses
Number of subjects: 37
Study 7630678 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T)
Number of subjects: 37
Study 7630678 — intervention group
Group type: COMPARATOR
Intervention: Prior zidovudine (ZDV) therapy
Number of subjects: 37
Study 2756920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A capsules
Number of subjects: 300
Study 2756920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 300
Study 781610 — intervention group
Group type: EXPERIMENTAL
Intervention: K-P diet (diet eliminating artificial flavors, colors, and natural salicylates)
Number of subjects: 15
Study 781610 — intervention group
Group type: EXPERIMENTAL
Intervention: K-P diet
Number of subjects: 15
Study 781610 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 15
Study 31872894 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare© (EBP implementation)
Number of subjects: 102
Study 31872894 — intervention group
Group type: COMPARATOR
Intervention: Control group (services as usual)
Number of subjects: 102
Study 31141807 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 0
Study 28601388 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab with etoposide and carboplatin or cisplatin
Number of subjects: 185
Study 28601388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab with etoposide and carboplatin or cisplatin
Number of subjects: 185
Study 28601388 — intervention group
Group type: COMPARATOR
Intervention: Placebo with etoposide and carboplatin or cisplatin
Number of subjects: 185
Study 28601388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab
Number of subjects: 185
Study 25968004 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) program, completed over 10 weeks with six lessons.
Number of subjects: 4050
Study 25968004 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the same iCBT after 12 months.
Number of subjects: 4050
Study 23783784 — intervention group
Group type: EXPERIMENTAL
Intervention: PLBs under the guidance of the navigation system
Number of subjects: 52
Study 23783784 — intervention group
Group type: COMPARATOR
Intervention: PLBs under the guidance navigation system with a low-dose (LD) protocol
Number of subjects: 52
Study 21847802 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial/behavioral intervention for poststroke depression
Number of subjects: 0
Study 19318446 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral DHEA/day
Number of subjects: 23
Study 19318446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17341993 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 47
Study 17341993 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 47
Study 17341993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with valsartan and amlodipine
Number of subjects: 47
Study 17341993 — intervention group
Group type: COMPARATOR
Intervention: Valsartan or Amlodipine (after 8 weeks)
Number of subjects: 47
Study 15194584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg/day)
Number of subjects: 201
Study 15194584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 15194584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with knee swelling)
Number of subjects: 201
Study 15194584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (in patients with knee swelling)
Number of subjects: 201
Study 11283391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 11283391 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age cutoff for study entry
Number of subjects: 90
Study 11283391 — intervention group
Group type: EXPERIMENTAL
Intervention: Wider time window for study entry
Number of subjects: 90
Study 11283391 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater stroke severity
Number of subjects: 90
Study 11283391 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean age of enrollees
Number of subjects: 90
Study 11283391 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate models
Number of subjects: 90
Study 9395946 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP support
Number of subjects: 20
Study 9395946 — intervention group
Group type: COMPARATOR
Intervention: Ordinary oxygen mask treatment (control group)
Number of subjects: 20
Study 8485268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 81
Study 8485268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8485268 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin and Placebo
Number of subjects: 81
Study 3481307 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide plus 600 mg mofebutazone
Number of subjects: 10
Study 3481307 — intervention group
Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 10
Study 31098717 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 0
Study 31098717 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 0
Study 31098717 — intervention group
Group type: EXPERIMENTAL
Intervention: Postsurgical supervised exercise
Number of subjects: 0
Study 31098717 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 0
Study 31098717 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0
Study 31098717 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0
Study 31098717 — intervention group
Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 0
Study 31098717 — intervention group
Group type: COMPARATOR
Intervention: Neurogenic pain medication
Number of subjects: 0
Study 31098717 — intervention group
Group type: COMPARATOR
Intervention: Muscle relaxants
Number of subjects: 0
Study 31098717 — intervention group
Group type: COMPARATOR
Intervention: Decompression combined with instrumented fusion
Number of subjects: 0
Study 29512813 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type I with 24 mL 0.375% ropivacaine per side
Number of subjects: 60
Study 29512813 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 60
Study 27559950 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with behavioral approach (NSEB)
Number of subjects: 194
Study 27559950 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 194
Study 27559950 — intervention group
Group type: COMPARATOR
Intervention: Prescribed physical activity (PPA)
Number of subjects: 194
Study 24748353 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early skin-to-skin contact (SSC)
Number of subjects: 0
Study 23147455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 74)
Number of subjects: 225
Study 23147455 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of zonisamide (n = 76)
Number of subjects: 225
Study 20404311 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT genotype (Met/Met, Met/Val, Val/Val) in white subjects
Number of subjects: 2858
Study 20404311 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT genotype (Met/Met, Met/Val, Val/Val) in black subjects
Number of subjects: 2858
Study 18946293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (4.0 mg/kg)
Number of subjects: 74
Study 18946293 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (70 microg/kg) plus glycopyrrolate (14 microg/kg)
Number of subjects: 74
Study 15976804 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Number of subjects: 46
Study 15976804 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 46
Study 12364736 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Number of subjects: 11
Study 10426608 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet group (received an information leaflet prior to attending the clinic)
Number of subjects: 200
Study 10426608 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 200
Study 7589604 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC and interferon
Number of subjects: 26
Study 7589604 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 2123561 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 0
Study 2123561 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated aspirin
Number of subjects: 0
Study 2123561 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 7408650 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (50-150 micrograms daily)
Number of subjects: 213
Study 7408650 — intervention group
Group type: COMPARATOR
Intervention: Iodine-containing salt (control)
Number of subjects: 213
Study 31774566 — intervention group
Group type: EXPERIMENTAL
Intervention: F-652 (10, 30 or 45 μg/kg) administered on day-1 and 7
Number of subjects: 18
Study 27225890 — intervention group
Group type: EXPERIMENTAL
Intervention: MP‐UKA
Number of subjects: 108
Study 27225890 — intervention group
Group type: COMPARATOR
Intervention: CI‐UKA
Number of subjects: 108
Study 26062182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture to restore consciousness combined with hyperbaric oxygen treatment
Number of subjects: 41
Study 26062182 — intervention group
Group type: COMPARATOR
Intervention: Simple hyperbaric oxygen treatment
Number of subjects: 41
Study 23546472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (%LV with LGE <6%)
Number of subjects: 46
Study 23546472 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (%LV with LGE ≥6%)
Number of subjects: 46
Study 21336131 — intervention group
Group type: EXPERIMENTAL
Intervention: alanine‐glutamine dipeptide‐supplemented total parenteral nutrition
Number of subjects: 127
Study 21336131 — intervention group
Group type: COMPARATOR
Intervention: control total parenteral nutrition
Number of subjects: 127
Study 19370333 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery in patients < 1 year of age
Number of subjects: 124
Study 17311603 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol laxative (17 g daily for 12 months)
Number of subjects: 311
Study 15055890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (n = 54)
Number of subjects: 113
Study 15055890 — intervention group
Group type: COMPARATOR
Intervention: Epidural (n = 59)
Number of subjects: 113
Study 11673100 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support systems (CDSS)
Number of subjects: 0
Study 11673100 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental or randomized controlled clinical trials (RCT)
Number of subjects: 0
Study 11673100 — intervention group
Group type: COMPARATOR
Intervention: Field tests of CDSS
Number of subjects: 0
Study 11673100 — intervention group
Group type: COMPARATOR
Intervention: Evaluation literature
Number of subjects: 0
Study 9627610 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐Octylcyanoacrylate (2‐OCA)
Number of subjects: 83
Study 9627610 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable sutures/staples
Number of subjects: 83
Study 7836506 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (buserelin, 500 micrograms/day s.c.)
Number of subjects: 40
Study 7836506 — intervention group
Group type: COMPARATOR
Intervention: Conventional HMG and HCG protocol
Number of subjects: 40
Study 2970787 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoperfusion catheter
Number of subjects: 0
Study 2970787 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon catheter
Number of subjects: 0
Study 26855561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin with probenecid (1.5 g divided into three doses within 25 hours)
Number of subjects: 24
Study 26855561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin with cimetidine (400 mg thrice daily for 7 days)
Number of subjects: 24
Study 26855561 — intervention group
Group type: COMPARATOR
Intervention: Nemonoxacin alone
Number of subjects: 24
Study 26855561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin with probenecid or cimetidine
Number of subjects: 24
Study 24417404 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse concentrated ambient particles (CAP) exposure for 2 hours
Number of subjects: 32
Study 22124610 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite sealants
Number of subjects: 407
Study 22124610 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-carbomer sealants
Number of subjects: 407
Study 22124610 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer sealants with energy supplied
Number of subjects: 407
Study 22124610 — intervention group
Group type: COMPARATOR
Intervention: High-viscosity glass-ionomer sealants without energy supplied
Number of subjects: 407
Study 20236813 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted lactose-free formula fortified with S. boulardii (26mg/100ml), n=34
Number of subjects: 70
Study 20236813 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (control), n=36
Number of subjects: 70